US45337C1027 - INCY - 896133 (XNAS)
INCYTE CORP Aktie
68,82 USD
Aktuelle Kurse von INCYTE CORP
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
INCY
|
USD
|
20.12.2024 22:36
|
68,82 USD
| 67,06 USD | 2,62 % |
London |
0J9P.L
|
USD
|
20.12.2024 15:35
|
67,60 USD
| 67,06 USD | 0,80 % |
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 0,39 % | -2,23 % | 4,69 % | 8,86 % | 9,41 % | -23,62 % |
Firmenprofil zu INCYTE CORP Aktie
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Investierte Fonds
Folgende Fonds haben in investiert: INCYTE CORP investiert:
Fonds | Vol. in Mio 562,22 | Anteil (%) 1,32 % |
Fonds | Vol. in Mio 659,98 | Anteil (%) 0,18 % |
Fonds | Vol. in Mio 3,86 | Anteil (%) 0,14 % |
Fonds | Vol. in Mio 147,77 | Anteil (%) 0,14 % |
Fonds | Vol. in Mio 214,38 | Anteil (%) 0,12 % |
Unternehmensdaten zur INCYTE CORP Aktie
Name INCYTE CORP
Firma Incyte Corporation
Symbol INCY
Website https://www.incyte.com
Heimatbörse
NASDAQ
WKN 896133
ISIN US45337C1027
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Herve Hoppenot
Marktkapitalisierung 13 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 2,5 T
Adresse 1801 Augustine Cut-Off, 19803 Wilmington
IPO Datum 1993-11-04
Aktien-Splits
Datum | Split |
---|---|
01.09.2000 | 2:1 |
10.11.1997 | 2:1 |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | ICY.F |
London | 0J9P.L |
NASDAQ | INCY |
Weitere Aktien
Investoren die INCYTE CORP die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.